These days, you hear plenty about Web 2.0 and how it is revolutionizing the way people use the Internet. Pathologist Keith Kaplan, M.D., at the Mayo Clinic uses the term “Pathology 2.0” to describe how use of Web 2.0 technology will similarly transform the anatomic pathology profession. Now comes interesting evidence that Pathology 2.0 is advancing as a trend. On August 24, the American Association of Bioanalysts (AAB) issued a press release touting its new digital proficiency testing (PT) service for whole-slide digital imaging. AAB offers images for PT that can be accessed through a standard web browser, using a free plug-in.
MORE ON: Path 2.0
AAB says that its whole-slide digital image PT allows the pathologist “to view a slide on a computer as you would view it on a microscope—zoom to any magnification up to oil immersion, adjust color, contrast, and move in any direction. You can use the micrometer to measure any object in the field of view.” By its introduction of a whole-slide digital imaging PT service, AAB is indicating that it believes adoption of digital imaging in anatomic pathology has advanced enough to make this proficiency testing service viable.
APERIO EARNS ISO 13485 CERTIFICATION
Staying on the subject of digital imaging, last week Aperio Technologies, Inc., of Vista, California, announced its certification as compliant with ISO 13485:2003. This involves “the design, manufacture, distribution, and servicing of digital image analysis systems and digital scanning services.” It used BSI Group as its registrar. BSI is a global player in ISO registrar and consulting services.
QUEBEC REVIEWING BREAST BIOPSIES
This spring, health system authorities determined that some laboratories in Quebec may have reported inaccurate results for breast cancer tests. Initially it was announced that breast cancer tests for 2,100 women would be independently reviewed for accuracy. Then, last month, the health minister announced that another 630 breast cancer tests would be added to the independent review. Laboratories in provinces outside of Quebec are handling these case reviews. It is anticipated that their findings will be released before the end of the year.
Dark Daily Update
Have you caught the latest e-briefings from DARK Daily? If so, then you’d know about…
…efforts by Neogenomics, Inc., to develop a FISH-Based assay for diagnosis of melanoma, using proprietary probes licensed fro m Abbott Laboratories. Target for market introduction is 2010. You can get the free DARK Daily e-briefings by signing up at www.darkdaily.com.